Scientists at LMU Munich and Helmholtz Munich have developed a groundbreaking CRISPR-based tool called TAPIR (Targeted Activation of Protein Translation) that gives researchers direct control over how much protein a cell produces — a discovery that could reshape the understanding and treatment of diseases ranging from rare developmental disorders to aggressive cancers.

Published in the journal Science, the study provides the first direct evidence that ribosomal RNA (rRNA) — long thought to be a passive structural component of the protein-making machinery — actively drives protein production. By using TAPIR to boost rRNA levels, the team showed they could significantly increase protein synthesis in cells.

"Our new study shows that targeted activation of rRNA production significantly increases protein synthesis," said Professor Stefan H. Stricker of LMU's Biomedical Center and Helmholtz Munich, lead author of the publication.

A Tale of Two Diseases

The implications of controlling protein output are dramatic — and context-dependent. When the team tested TAPIR in a mouse model of Treacher-Collins syndrome, a rare congenital disorder caused by impaired ribosome function, stimulating rRNA production partially compensated for disease-related changes. The approach shows promise for conditions where cells cannot make enough functional ribosomes.

But the same intervention had the opposite effect in cancer. In a pancreatic cancer mouse model, boosting rRNA production accelerated tumor growth — directly demonstrating that elevated rRNA is not merely a consequence of cancer but an active driver of malignancy.

"Our study clearly shows that the regulation of protein biosynthesis plays a key role both in processes of development and growth and in the development of cancer," Stricker said.

A Platform for the Future

The team views TAPIR primarily as a research platform. By giving scientists a way to deliberately alter rRNA production and observe what follows, it opens new avenues for understanding how protein synthesis influences stem cell behavior, development, and disease. Future work could explore whether carefully calibrated control of rRNA production could yield new therapeutic targets for disorders on both ends of the protein spectrum — too little in developmental diseases, too much in cancer.

Sources